Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 3/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002144 | 1.00 | ALOX5AP (0.45) | ALOX5APFEN1FFAR4SCN9ATRPA1 | |
| SCHEMBL12570859 | 0.87 | FFAR4 (0.47) | ALOX5APFEN1FFAR4SCN9ATRPA1 | |
| SCHEMBL29225791 | 0.80 | PTPRC (0.50) | ALOX5APFEN1CASR | |
| SCHEMBL30913862 | 0.80 | PTPRC (0.50) | ALOX5APFEN1CASR | |
| SCHEMBL1045874 | 0.80 | FFAR4 (0.51) | ALOX5APFEN1FFAR4SCN9ATRPA1 | |
| SCHEMBL14744155 | 0.78 | NCOA1 (0.51) | ALOX5APFEN1FFAR4SCN9ATRPA1 | |
| SCHEMBL29788132 | 0.77 | FFAR4 (0.55) | ALOX5APFEN1FFAR4SCN9ATRPA1 | |
| SCHEMBL306822 | 0.77 | FFAR4 (0.55) | ALOX5APFEN1FFAR4SCN9ATRPA1 | |
| SCHEMBL29225818 | 0.76 | DPP4 (0.46) | ALOX5APFEN1FFAR4TRPA1CASR | |
| SCHEMBL2095253 | 0.75 | FFAR4 (0.50) | ALOX5APFEN1FFAR4SCN9ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | ALOX5AP 1784/4885FEN1 3393/4885FFAR4 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.